6JU Stock Overview
BioCardia, Inc., a clinical-stage regenerative medicine company, engages in development of cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 1/6 |
| Dividends | 0/6 |
BioCardia, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.34 |
| 52 Week High | US$2.56 |
| 52 Week Low | US$0.01 |
| Beta | 1.49 |
| 1 Month Change | -5.59% |
| 3 Month Change | -27.78% |
| 1 Year Change | -81.73% |
| 3 Year Change | -88.54% |
| 5 Year Change | n/a |
| Change since IPO | -80.00% |
Recent News & Updates
Recent updates
Shareholder Returns
| 6JU | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 5.0% | 0.8% | 1.2% |
| 1Y | -81.7% | -24.4% | 2.0% |
Return vs Industry: 6JU underperformed the German Biotechs industry which returned -24.4% over the past year.
Return vs Market: 6JU underperformed the German Market which returned 2% over the past year.
Price Volatility
| 6JU volatility | |
|---|---|
| 6JU Average Weekly Movement | 14.3% |
| Biotechs Industry Average Movement | 4.9% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 10.1% |
| 10% least volatile stocks in DE Market | 2.5% |
Stable Share Price: 6JU's share price has been volatile over the past 3 months.
Volatility Over Time: 6JU's weekly volatility has decreased from 579% to 14% over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 18 | Peter Altman | www.biocardia.com |
BioCardia, Inc., a clinical-stage regenerative medicine company, engages in development of cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases. Its lead therapeutic candidate is the CardiAMP, an autologous mononuclear cell therapy system for the treatment of heart failure and chronic myocardial ischemia; and allogeneic cell therapy for cardiac and pulmonary disease. The company is also developing allogeneic cells therapeutic platform, an investigational culture expanded bone marrow derived mesenchymal cell therapy, which is in Phase I/II trial for the treatment of ischemic heart failure.
BioCardia, Inc. Fundamentals Summary
| 6JU fundamental statistics | |
|---|---|
| Market cap | €9.44m |
| Earnings (TTM) | -€10.79m |
| Revenue (TTM) | €444.90k |
20.8x
P/S Ratio-0.9x
P/E RatioIs 6JU overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 6JU income statement (TTM) | |
|---|---|
| Revenue | US$477.00k |
| Cost of Revenue | US$7.73m |
| Gross Profit | -US$7.25m |
| Other Expenses | US$4.32m |
| Earnings | -US$11.57m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.43 |
| Gross Margin | -1,519.71% |
| Net Profit Margin | -2,425.79% |
| Debt/Equity Ratio | 0% |
How did 6JU perform over the long term?
See historical performance and comparison